Division of Internal Medicine, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA.
Division of Medical Oncology, Bartlett, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA.
Curr Oncol Rep. 2020 Mar 21;22(4):39. doi: 10.1007/s11912-020-0897-9.
While immune checkpoint inhibitor (ICI) therapy has improved melanoma patient outcomes, it has also resulted in the rise of unique immune-related adverse events (irAEs). Here, we review and synthesize irAE management recommendations from several oncological societies into a streamlined format to aid in diagnosis and management. We also include clinical pearls highlighting several recent research studies in this field.
Knowledge of immunotherapy toxicity has continually evolved, and several major oncologic societies have recently released new or updated guidelines. Keeping up with the evolving field of immunotherapy and related toxicities is crucial, because ICI use, in combination with other agents, will only continue to increase and likely result in new and different patterns of irAEs. Providing clear and concise references for clinicians will help ensure proper irAE evaluation and management going forward. We present one such reference here, covering management of common and/or serious irAEs.
虽然免疫检查点抑制剂（ICI）治疗改善了黑色素瘤患者的预后，但也导致了独特的免疫相关不良事件（irAE）的增加。在这里，我们将来自多个肿瘤学会的 irAE 管理建议进行综述和综合，形成一个简化的格式，以帮助诊断和管理。我们还包括了一些最近在该领域的临床研究的亮点。
对免疫治疗毒性的认识不断发展，最近几个主要的肿瘤学会已经发布了新的或更新的指南。紧跟免疫治疗和相关毒性的不断发展的领域至关重要，因为 ICI 的使用，结合其他药物，只会继续增加，并可能导致新的和不同的 irAE 模式。为临床医生提供清晰简洁的参考资料将有助于确保未来正确评估和管理 irAE。我们在这里提供了这样的一个参考，涵盖了常见和/或严重 irAE 的管理。
